1Motzer RJ,Hutson TE,Tomczak P,et,al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol,2009,27:3584-3590.
2Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med,2007,356:115-124.
3Escudier B,Roigas J,Gillessen S,et al.Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.J Clin Oncol,2009,27:4068-4075.
4Rivera F,Benounna M,Sánchez de la Nieta MD.Sunitinib-aggravated hypertension.J Hypertens,2009,27:1502-1503.
5Bello CL,Garrett M,Sherman L,et al,Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.Cancer Chemother Pharmacol,2010,66:699-707.
6Kollmannsberger C,Soulieres D,Wong R,et al.Sunitinib therapy for metastatic renal cell carcinoma:recommendations for management of side effects.Can Urol Assoc J,2007,1 (2 Suppl):S41-54.
